Metropolis Healthcare Limited announced its Q3FY26 quarterly results for the quarter ended December 31, 2025, demonstrating robust financial performance alongside significant corporate developments. The diagnostic services company's Board of Directors approved comprehensive quarterly results and strategic initiatives during their meeting held on February 4, 2026.

Strong Financial Performance

The company delivered impressive consolidated financial results with revenue reaching ₹4.06 billion compared to ₹3.2 billion in the corresponding quarter of the previous year, marking substantial growth year-on-year. Consolidated net profit demonstrated strong momentum at ₹414 million versus ₹314 million in the year-ago quarter, representing a robust 31% increase.

Operational Excellence and Margin Expansion

The company's operational performance showcased significant improvement with EBITDA reaching ₹948 million compared to ₹720 million in the year-ago quarter, reflecting a strong 32% year-on-year growth. EBITDA margin expanded to 23.36% from 22.31% in the corresponding quarter of the previous year, demonstrating enhanced operational efficiency and productivity gains across the diagnostic services portfolio.

Major Corporate Developments

The Board of Directors approved several significant strategic initiatives during their meeting. Most notably, they recommended a bonus issue of equity shares in the proportion of 3:1, meaning shareholders will receive 3 fully paid-up equity shares of face value INR 2 each for every 1 existing share held. The bonus issue is subject to members, statutory and regulatory approvals, with the record date to be announced in due course.

Regulatory Filing and Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company filed its investor presentation for the quarter ended December 31, 2025, on February 04, 2026. The presentation, signed by Kamlesh C Kulkarni, Head Legal & Secretarial, has been uploaded on the company's website at www.metropolisindia.com and provides comprehensive insights into the company's Q3FY26 performance.

The meeting commenced at 11:15 AM IST and concluded at 3:40 PM IST, with comprehensive discussions on quarterly performance and strategic initiatives that position the company for continued growth in the diagnostic services sector.

Metropolis healthcare has completed the allotment of equity shares to employees under its employee stock compensation program. The Nomination and Remuneration Committee approved the allotment through a circular resolution dated January 13, 2026, demonstrating the company's commitment to employee incentivization through equity participation.

Share Allotment Details

The allotment encompasses 9,960 equity shares issued under the Metropolis Restrictive Stock Unit Plan 2020. The key parameters of this allotment are presented below:

Post-Allotment Capital Structure

Following this equity allotment, the company's capital structure has been updated accordingly. The distinctive numbers for the newly allotted shares range from 5,18,21,983 to 5,18,31,942 (both inclusive).

Lock-in Provisions and Share Rights

The allotted equity shares are subject to specific lock-in arrangements designed to ensure employee retention and alignment with company objectives. Under the terms of the MHL-RSU Plan 2020:

• 50% of the equity shares allotted to each RSU holder are subject to lock-in restrictions
• The lock-in period extends for one year from the date of allotment
• Lock-in expiry date is set for January 13, 2027
• All newly allotted shares rank pari-passu with existing equity shares in all respects

Regulatory Compliance

The allotment has been conducted in full compliance with regulatory requirements under SEBI regulations. The company obtained necessary approvals from both BSE Limited (Case No. 130335) and National Stock Exchange of India Ltd. (Application No. 27089). The original filing for the employee benefits scheme was completed on May 23, 2021, with in-principle approvals received from both exchanges in June 2021.

The shares have been issued in dematerialized form and will be available for trading subject to the applicable lock-in provisions. The company has fulfilled all disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.